SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) announced its featured placement in a BioMedWire editorial examining next-generation innovation in the rapidly expanding GLP-1 therapeutic market. The editorial highlights the company's subsidiary GlucaPharm Inc. and its development of GEP-44, a novel triple agonist peptide designed to enhance efficacy, tolerability and delivery flexibility in the treatment of obesity, type 2 diabetes and related metabolic conditions.
The GLP-1 market has seen explosive growth with drugs like Ozempic and Wegovy, but innovation continues as companies seek improved formulations. GEP-44 aims to differentiate through improved tolerability and potential non-injectable delivery, addressing key patient barriers. The full editorial can be accessed at https://ibn.fm/rq75B.
SureNano Science is transitioning from its initial business of distributing the SureNano surfactant—a food-grade compound for nanoemulsions—into a pharmaceutical-focused company. The acquisition of GlucaPharm positions it to compete in the metabolic disease space. The company holds an exclusive license to distribute the SureNano surfactant in Canada, Oklahoma, and Colorado.
The editorial's focus on GLP-1 innovation comes as the global obesity and diabetes markets continue to expand. Analysts project the GLP-1 receptor agonist market could exceed $100 billion annually by 2030. GEP-44's triple agonist mechanism, targeting multiple receptors, may offer advantages over current single- or dual-agonist therapies. If successful, it could capture significant market share and provide new treatment options for patients.
For investors, the news signals SureNano's strategic pivot toward high-growth therapeutic areas. The company's progress with GEP-44 will be closely watched as it advances through development stages. The latest news and updates relating to SURNF are available at https://ibn.fm/SURNF.
This announcement was disseminated by InvestorWire, a platform for press release syndication. InvestorWire is part of IBN's Dynamic Brand Portfolio, providing distribution and communications solutions. The company's newsroom contains additional information on SureNano Science.
